

RECEIVED  
OPPT CBIC

2007 JAN 20 AM 7:38

**FINAL SUBMISSION TO THE  
HIGH PRODUCTION VOLUME (HPV)  
CHEMICAL CHALLENGE PROGRAM**

**For**

**2, 4, 8, 10-Tetraoxa-3,9-diphosphaspiro[5.5]undecane, 3,9-bis[2,4-bis(1,1-dimethylethyl)phenoxy]-**

**CAS No. 26741-53-7**

**Submitted to the US EPA**

**BY**

**Chemtura (formerly Crompton) Corporation  
January 2007**

## Table of Contents

Test Plan for 2, 4, 8, 10-Tetraoxa-3,9-diphosphaspiro[5.5]undecane, 3,9-bis[2,4-bis(1,1-dimethylethyl)phenoxy]-

1. General Information.....	3
1.1 CAS No. ....	3
1.2 Molecular weight .....	3
1.3 Structure and formula .....	3
1.4 Introduction .....	3
2. Review of Existing Data .....	3
A. Evaluation of Physicochemical Data.....	4
B. Evaluation of Environmental Fate Data .....	5
C. Evaluation of Ecotoxicity Data .....	5
D. Evaluation of Human Health Effects Data .....	6
3. Evaluation of Data for Quality and Acceptability .....	8
4. References.....	8


Appendix 1: Additional Robust Summaries

## 1. General Information

1.1 CAS Number: 26741-53-7

1.2 Molecular Weight: 604.71

1.3 Structure and formula:  $C_{33}H_{50}O_6P_2$



## 1.4 Introduction

2,4,8,10-Tetraoxa-3,9diphosphaspiro[5.5]undecane,3,9-bis[2,4-bis(1,1-dimethylethyl)phenoxy]- (Ultrinox 626) is used as an antioxidant for polyolefins, polyesters, styrenics, engineering thermoplastics, PVC, elastomers and adhesives. The use of Ultrinox 626 is sanctioned by the FDA for food contact applications under 21 CFR 178.2010 covering antioxidants and/or stabilizers for polymers.

## 2. Review of Existing Data

Chemtura Corporation has undertaken a comprehensive evaluation of all relevant data on the SIDS endpoints of concern for Ultrinox 626.

The availability of the data on the specific SIDS endpoints is summarized in Table 1.

**Table 1: Available adequate data on Ultrinox 626**

CAS NO. 26741-53-7	Information Available?	GLP	OECD Study?	Other Study?	Estimation Method?	Acceptable?	SIDS Testing Required?
	Y/N	Y/N	Y/N	Y/N	Y/N	Y/N	Y/N
<b>Physicochemical</b>							
Melting Point	Y	Y	Y			Y	N
Boiling Point	Y	Y	Y			Y	N
Vapour Pressure	Y				Y	Y	N
Water Solubility	Y				Y	N	N
Partition Coefficient (Kow)	Y				Y	Y	N

<b>Environmental Fate</b>							
Biodegradation	Y				Y	Y	N
Hydrolysis	N				Y	Y	N
Photodegradation	Y				Y	Y	N
Transport and Distribution between Environmental Compartments	Y				Y	Y	N
<b>Ecotoxicology</b>							
Acute Fish	Y				Y	Y	N
Acute Daphnia	Y				Y	Y	N
Acute Algae	Y				Y	Y	N
<b>Toxicology</b>							
Acute Oral	Y	N	N			Y	N
Repeat Dose toxicity	Y	N	N			Y	N
Genetic toxicity – Gene mutation	Y	N				Y	N
Genetic toxicity – Chromosome Aberration	Y	Y	Y			Y	N
Reproductive toxicity	Y	N	N			Y	N
Developmental toxicity/teratogenicity	Y	N	N			Y	N

#### A. Evaluation of Physiochemical Data

##### 1. Melting Point

The melting point was found to be between 173 - 180°C in a guideline study conducted to GLP.

##### 2. Boiling Point

The boiling point was found to be greater than 311°C in a guideline study conducted to GLP.

##### 3. Vapour Pressure

The vapor pressure was estimated to be  $2.9 \times 10^{-12}$  hPa at 25°C using MPBPWIN v 1.40.

##### 4. Water Solubility

The water solubility is estimated to be  $5.67 \times 10^{-8}$  mg/L at 25°C using WSKOW v 1.40.

##### 5. Partition Coefficient

The log Pow is estimated to be 10.9 using KOWWIN v 1.66.

#### Summary of Physicochemical Properties Testing: data for melting point, boiling

point, vapour pressure, partition coefficient and water solubility are considered to fill these endpoints adequately.

## **B. Evaluation of Environmental Fate Data**

### **1. Biodegradation**

The biodegradability of the chemical has been estimated using Biowin v4.00 and the results indicate the chemical to not be readily biodegradable. The chemical contains no biodegradable groups, therefore no biodegradation testing is proposed.

### **2. Hydrolysis**

A GLP study was conducted and it was determined that due to the poor solubility of the test substance in water, a half-life could not be determined. The Fugacity model calculated half-life was 3.6 e003.

### **3. Photodegradation**

The potential for photodegradation of Ultrinox 626 has been estimated using the AOPWIN v1.90, and indicated atmospheric oxidation via OH radicals reaction with a half-life of 1.166 hours.

### **4. Transport and Distribution between Environmental Compartments**

An Epiwin Level III Fugacity Model calculation has been conducted Ultrinox 626 and indicates distribution mainly to sediment and, to a lesser extent, soil for emissions of 1000 kg/hr simultaneously to air water and soil compartments.

**Summary of Environmental Fate Testing: data for photodegradation, hydrolysis, biodegradation and transport and distribution between environmental compartments are considered to fill these endpoints adequately.**

## **C. Evaluation of Ecotoxicity Data**

### **1. Acute Toxicity to Fish**

The  $LC_{50}$  (96 h) was estimated to be  $1.93 \times 10^{-6}$  mg/L using ECOSAR v 0.99g. This is greater than the estimated limit of solubility of the substance.

### **2. Acute Toxicity to Daphnia**

The  $EC_{50}$  (48 h) was estimated to be  $3.82 \times 10^{-6}$  mg/L using ECOSAR v 0.99g. This is greater than the estimated limit of solubility of the substance.

### 3. Acute Toxicity to Algae

The EC<sub>50</sub> (96 h) was estimated to be  $3.99 \times 10^{-6}$  mg/L using ECOSAR v 0.99g. This is greater than the estimated limit of solubility of the substance.

**Summary of Ecotoxicity Testing: Ultrinox 626 is estimated to be toxic to the environment only at levels above its limit of solubility. These data are considered to fill these endpoints adequately.**

### D. Evaluation of Human Health Effects Data

#### 1. Acute Oral Toxicity

The acute oral toxicity of Ultrinox 626 is reported as LD<sub>50</sub> = 5580 mg/kg bw in a rat study. In a study conducted using Leghorn hens, an LD<sub>50</sub> of >6080 mg/kg bw was reported.

#### 2. Acute Inhalation Toxicity (non-SIDS endpoint)

An LC<sub>50</sub> of >2000 mg/m<sup>3</sup> was reported in rats after a 1-hour exposure to Ultrinox 626.

#### 3. Acute Dermal Toxicity (non-SIDS endpoint)

Acute dermal toxicity was reported as LD<sub>50</sub> > 2000 mg/kg using rabbits in an OECD 402 study conducted to GLP.

#### 4. Acute I.P. Toxicity (non-SIDS endpoint)

An LD<sub>50</sub> (mouse) of 14.1 – 20.2 mg/kg is reported in the literature.

#### 5. Skin Irritation (non-SIDS endpoint)

Ultrinox 626 was found to be corrosive to rabbit skin in a study conducted to 16 CFR 1500.42.

#### 6. Sensitization (non-SIDS endpoint)

The substance was not sensitizing (0/10 sensitization rate) to guinea pigs in a study conducted to OECD 406 under GLP.

#### 7. Repeat Dose Toxicity

In a 90-day oral feed study conducted using rats, the observed NOAEL was 300 ppm (22-26 mg/kg/bw). Microscopic lesions seen in the livers and spleens of female rats in the 1000 ppm (78-91 mg/kg/day) group were considered to be substance related.

In a 4-month oral dose study conducted using dogs a NOAEL of 12 mg/kg b.w. was reported. Seven out of 8 dogs dosed at 40 mg/kg b.w. displayed degenerative myelin lesions, which were considered to be dose-related.

In a 2-year oral feed study using rats, a NOAEL of 500 ppm (highest dose tested) was reported.

No effects were seen at any of the dose levels used.

#### 8. Genotoxicity

Ultranox 626 tested negative in an Ames test using *Salmonella typhimurium* strains TA97, TA98, TA100 and TA102 and *Escherichia coli* strain WP2 (PKM 101) with and without metabolic activation.

In a chromosome aberration test (OECD 473) the substance tested positive without metabolic activation using Arochlor 1254-induced rat liver S9.

In an in vivo mouse micronucleus assay (OECD 474) no genotoxic effects were observed.

#### 9. Reproductive and Developmental Toxicity

Female rabbits were dosed orally at up to 200 mg/kg b.w./day with the substance on days 16-18 of gestation and the fetuses removed for examination on day 29 of gestation. No maternal effects were noted in any dose group. 3/15 rabbits miscarried in the high dose group, however the study authors considered this result to be only bordering significance. The number of implantations and the number and weight of the fetuses were not significantly different from the control values. There was no difference in the distribution between male and female fetuses and there were not significant numbers of malformations observed.

Reproductive organs were examined in the 2-year oral feed study in rats described in section 7 above. No greater frequency of anomalies was observed in treated rats compared to controls. In the interests of animal welfare, it is considered to be unnecessary to conduct a separate reproductive toxicity study based on the evidence available from the developmental toxicity study and the 2-year repeat dose study.

The test substance was fed in the diet to three groups of 20 male and 20 female rats for 90 days. The rats were observed daily for signs of overt toxicity and mortality. The following tissues from 10 males and 10 females from the control group and the 1000 ppm group were examined microscopically: adrenals, aorta, eye and optic nerve, esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, rectum, liver, trachea, spleen, pancreas, urinary bladder, bone



marrow (sternum), prostate/uterus, seminal vesicles, testes/ovaries, brain, heart, lung and bronchi, sciatic nerve, pituitary, thyroid and parathyroid, mesenteric lymph node, mandibular lymph node, spinal cord, salivary gland (submaxillary), skeletal muscle (thigh), skin, mammary gland, thymus, kidneys, any other tissue with gross lesions. There were no reproductive organ weight changes and no macroscopic or microscopic changes in reproductive organs examined up to the highest dose tested (1000 ppm). The NOAEL for reproductive effects is 1000 ppm.

**Summary of Human Health Effects Testing: All endpoints are considered to have been filled adequately.**

### **3. Evaluation of Data for Quality and Acceptability**

The collected data were reviewed for quality and acceptability following the general US EPA guidance [2] and the systematic approach described by Klimisch et al [3]. These methods include consideration of the reliability, relevance and adequacy of the data in evaluating their usefulness for hazard assessment purposes. This scoring system was only applied to ecotoxicology and human health endpoint studies per EPA recommendation [4]. The codification described by Klimisch specifies four categories of reliability for describing data adequacy. These are:

- (1) **Reliable without restriction:** Includes studies or data complying with Good Laboratory Practice (GLP) procedures, or with valid and/or internationally accepted testing guidelines, or in which the test parameters are documented and comparable to these guidelines.
- (2) **Reliable with Restrictions:** Includes studies or data in which test parameters are documented but vary slightly from testing guidelines.
- (3) **Not Reliable:** Includes studies or data in which there are interferences, or that use non-relevant organisms or exposure routes, or which were carried out using unacceptable methods, or where documentation is insufficient.
- (4) **Not Assignable:** Includes studies or data in which insufficient detail is reported to assign a rating, e.g. listed in abstracts or secondary literature.

### **4. References**

- [1] US EPA, EPI Suite Software, 2000
- [2] USEPA (1998). Guidance for Meeting the SIDS Requirements (The SIDS Guide). Guidance for the HPV Challenge Program. Dated 11/2/98.



- [3] Klimisch, H.-J., et al (1997). A Systematic Approach for Evaluating the Quality of Experimental Toxicological and Ecotoxicological Data. Regul. Toxicol. Pharmacol. 25: 1-5
- [4] USEPA (1999). Determining the Adequacy of Existing Data. Guidance for the HPV Challenge Program. Draft dated 2/10/99.